Business
Ensysce Biosciences Announces First Peer-Reviewed Clinical Publication Demonstrating Oral Overdose Protection with MPAR(R) Technology
~ Phase 1 Data Published in Journal of Opioid Management Validates First-in-Class Overdose-Limiting Opioid Technology of PF614-MPAR ~ SAN DIEGO, CA / ACCESS Newswire / March 3, 2026 /Ensysce Biosciences, Inc. (NASDAQ:ENSC) ("Ensysce" or the "Company"), ...
About this update from Ensysce Biosciences, Inc.
[{"type":"text","content":"~ Phase 1 Data Published in Journal of Opioid Management Validates First-in-Class Overdose-Limiting Opioid Technology of PF614-MPAR ~","length":133,"tagName":"p"},{"type":"text","content":"SAN DIEGO, CA / ACCESS Newswire / March 3, 2026 / Ensysce Biosciences, Inc. (NASDAQ:ENSC) ("Ensysce" or the "Company"), a clinical-stage pharmaceutical company pioneering next-generation pain and central nervous system therapeutics designed to minimize risk of abuse and overdose, today announced the publication of the first clinical manuscript describing its MPAR® (Multi-Pill Abuse Resistance) overdose protection technology.","length":448,"tagName":"p"},{"type":"text","content":"The paper, titled "Formulation and a Phase 1 Clinical Study of PF614-MPAR, an Oxycodone Prodrug with Oral Opioid Overdose Protection," appears online in the Journal of Opioid Management Jan/Feb 2026 issue.","length":215,"tagName":"p"},{"type":"text","content":"https://wmpllc.org/ojs/index.php/jom/article/view/3977","length":54,"tagName":"p"},{"type":"text","content":"PF614-MPAR is the first opioid candidate specifically designed to provide active protection against oral overdose-a limitation not addressed by currently marketed abuse-deterrent formulations. MPAR® technology is engineered to maintain therapeutic opioid exposure when taken as prescribed while automatically limiting additional opioid release when excessive numbers of pills are consumed.","length":389,"tagName":"p"},{"type":"text","content":"Data presented in the publication demonstrate that PF614-MPAR achieved appropriate opioid plasma levels under normal dosing conditions, while preventing large increases in opioid delivery when supratherapeutic doses were administered. These findings support the potential for a fundamentally new safety paradigm in opioid analgesia. MPAR® previously received Breakthrough Therapy Designation from the U.S. Food and Drug Administration (FDA) in January 2024 based on this clinical evidence and the technology is protected by a growing intellectual property portfolio extending through 2042.","length":589,"tagName":"p"},{"type":"text","content":""This peer-reviewed publication marks a defining milestone not only for Ensysce, but for the field of pain medicine," said Dr. Lynn Kirkpatrick, Chief Executive Officer of Ensysce. "CDC data p...